
via University of South Australia
A novel formulation of the prostate cancer drug abiraterone acetate – currently marketed as Zytiga – will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug’s effectiveness by 40 per cent.
Developed by Professor Clive Prestidge’s Nanostructure and Drug Delivery research group at UniSA’s Cancer Research Institute, the breakthrough discovery uses an oil-based oral formulation that not only enables a smaller dose of the drug to be effective, but also has the potential to dramatically reduce possible side effects, such as joint swelling and diarrhoea.
Despite Zytiga being the leading formulation to treat prostate cancer, lead researcher, Dr Hayley Schultz says the new formulation will ultimately provide a better treatment for patients with prostate cancer.
Prostate cancer is the most commonly diagnosed cancer in men, with one in six at risk of diagnosis before the age of 85.
In 2019, more than 19,500 cases of prostate cancer were diagnosed in Australia. Globally, prostate cancer cases reached 1.28 million in 2018.
“Many drugs are poorly water soluble, so when they’re ingested, they enter the gut but don’t dissolve, which means that their therapeutic effect is limited,” Dr Schultz says.
“This is the case for Zytiga. Here, only 10 per cent of the dose is absorbed, leaving the other 90 per cent undissolved, where it simply passes through the body as waste.
“On top of this, patients taking Zytiga must fast for two hours prior to taking the drug, and another hour after taking the drug to achieve predictable absorption. And as you can imagine, this can be painstakingly inconvenient.
“Our new formulation changes this. By using oils to mimic pharmaceutical food effects, we’re able to significantly increase the drug’s solubilisation and absorption, making it more effective and a far less invasive treatment for patients.”
The new formulation uses very high levels of abiraterone acetate dissolved within a specific oil and encapsulated within porous silica microparticles to form a powder that can be made into tablets or filled into capsules. Applied to human treatment, it could reduce the dose from 1000mg to 700mg per day, without the need for fasting.
Prof Prestidge says if the team can secure funding, clinical trials in humans could be just two years away.
“Based on our knowledge of this drug’s pharmaceutical food effect, we hypothesise its absorption in humans will be extensively improved using this technology”, Prof Prestidge says.
“Anything we can do to contribute to the development of a commercialised product to improve the lives of patients, is invaluable.
“This novel formulation is flexible enough to be adopted by thousands of different medicines; its potential to help patients of all kinds is exponential.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Prostate cancer treatment
- Considering the potential for gene-based therapy in prostate canceron February 26, 2021 at 4:03 am
Prostate cancer lends itself to gene therapies, and multiple aspects of prostate cancer care make gene therapy an appealing treatment option for this common malignancy. Although laboratory and ...
- Game Changing New Test Helps Doctors Find Hidden Prostate Canceron February 26, 2021 at 3:00 am
New technology is making it easier for doctors to detect prostate cancer in men and could prove to be an effective treatment for the disease. Kiet Do reports. (2-25-21) ...
- Prostate Cancer Market Size, Share, Industry Report, Trends, Growth and Forecast 2020-2027on February 26, 2021 at 12:09 am
Prostate Cancer Program offers a broad range of innovative diagnostic and treatment options to patients who have been diagnosed with prostate cancer. Request to Fill The Form To get Sample Copy of ...
- The Game Changer: New Test Helps Doctors Find Hidden Prostate Canceron February 25, 2021 at 11:38 pm
New technology is making it easier for doctors to detect prostate cancer in men and could prove to be an effective treatment for the disease.
- Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMAon February 25, 2021 at 7:38 am
Ultrasound imaging is routinely used to guide prostate biopsies, yet delineation of tumors within the prostate gland is extremely challenging, even with microbubble (MB) contrast. A more effective ...
Go deeper with Google Headlines on:
Prostate cancer treatment
Go deeper with Bing News on:
Prostate cancer
- Al Roker Reveals Why He's So Open About His Prostate Cancer Journeyon February 26, 2021 at 1:39 pm
In an appearance on The Dr. Oz Show, Al Roker opened up about being diagnosed with prostate cancer and why he's not afraid to speak publicly about it.
- Taking Action! Al Roker Tells Dr. Oz Why He Didn't Just 'Brush' His Prostate Cancer Diagnosis 'Under The Rug'on February 26, 2021 at 11:25 am
Al Roker joined Dr. Oz to talk about his prostate cancer and thoughts on the COVID-19 vaccine. Watch the interview, here.
- Considering the potential for gene-based therapy in prostate canceron February 26, 2021 at 4:03 am
Prostate cancer lends itself to gene therapies, and multiple aspects of prostate cancer care make gene therapy an appealing treatment option for this common malignancy. Although laboratory and ...
- Game Changing New Test Helps Doctors Find Hidden Prostate Canceron February 26, 2021 at 3:00 am
New technology is making it easier for doctors to detect prostate cancer in men and could prove to be an effective treatment for the disease. Kiet Do reports. (2-25-21) ...
- Prostate Cancer Market Size, Share, Industry Report, Trends, Growth and Forecast 2020-2027on February 26, 2021 at 12:09 am
Prostate Cancer Program offers a broad range of innovative diagnostic and treatment options to patients who have been diagnosed with prostate cancer. Request to Fill The Form To get Sample Copy of ...